시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 지연성 운동장애 치료 시장 보고서(2025년)
Tardive Dyskinesia Therapeutics Global Market Report 2025
상품코드 : 1769768
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,263,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,052,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,842,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 지연성 운동장애 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년 연평균 성장률(CAGR) 7.2%, 41억 1,000만 달러로 성장할 전망이며, 이 성장 예측에 기여하는 치료 요인 증가 요법 접근에 대한 경사 증가, 헬스 케어 인프라의 강화 등을 들 수 있습니다. 이 기간에 예측되는 주요 동향에는 제약 기업과 연구 기관의 전략적 제휴, 장시간 작용형 제제의 개발, 제네릭 의약품의 도입, 희귀의약품과 같은 규제상의 메리트, 약물전달 기술의 혁신 등이 있습ㄴ디ㅏ.

정신질환 유병률 상승은 향후 몇 년간의 지연성 운동장애 치료 시장의 성장을 견인할 것으로 예측됩니다. 디지털 커뮤니케이션의 보급과 페이스의 빠른 라이프 스타일의 요구에 의해 의미있는 대면에서의 교류가 감소하고, 외로움 과 감정적 긴장 증가로 이어지고 있습니다. 환자를 돕는데 중요한 역할을 하고 있습니다. 그 결과, 치료의 어드히어런스와 삶의 질 전체가 향상됩니다. 2024년 National Alliance on Mental Illness는 미국의 18-44세 개인에서 정신병 스펙트럼과 기분 장애가 연간 약 60만 건의 입원의 원인이 되고 있다고 보고하고 있습니다.

지연성 운동장애 치료 시장의 주요 기업은 체내 약물 수준을 더욱 안정화시키기 위해 1일 1회 치료 옵션과 같은 고급 제품을 개발하는 데 주력하고 있습니다. 2024년 5월, 이스라엘에 본사를 둔 바이오 의약품 회사인 Teva Pharmaceutical Industries Limited는 헌팅턴 병과 관련된 지연성 운동장애 성인 환자를 대상으로 한 AUSTEDO XR 정제의 미국 FDA 승인을 받았습니다. AUSTEDO XR은 1일 1회 복용으로 효과적으로 증상을 조절할 수 있으며, 현재 30mg, 36mg, 42mg, 48mg의 4가지 용량으로 제공되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

JHS
영문 목차

영문목차

Tardive dyskinesia therapeutics are treatments aimed at alleviating or controlling the involuntary, repetitive movements associated with this neurological condition. These therapies focus on addressing the neurological disruptions commonly linked to long-term use of specific medications. Their primary objective is to enhance the patient's quality of life by decreasing the intensity and occurrence of motor symptoms, improving functional capabilities, and preventing chronic complications.

Key medications in the tardive dyskinesia therapeutics market include deutetrabenazine, valbenazine, and others. Deutetrabenazine, a vesicular monoamine transporter type 2 (VMAT2) inhibitor, is specifically utilized to manage involuntary movements related to tardive dyskinesia. It is available in various forms such as solid dosage (tablets and capsules), liquid forms, and injections. The drug is applied in cases of antipsychotic-induced tardive dyskinesia, other drug-induced types, and idiopathic tardive dyskinesia. It is administered across multiple end-user environments including hospitals, clinics, specialty treatment centers, and homecare settings.

The tardive dyskinesia therapeutics market research report is one of a series of new reports from The Business Research Company that provides tardive dyskinesia therapeutics market statistics, including tardive dyskinesia therapeutics industry global market size, regional shares, competitors with a tardive dyskinesia therapeutics market share, detailed tardive dyskinesia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the tardive dyskinesia therapeutics industry. This tardive dyskinesia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tardive dyskinesia therapeutics market size has grown strongly in recent years. It will grow from $2.90 billion in 2024 to $3.12 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. This growth during the historical period can be linked to an increasing prevalence of tardive dyskinesia, a rising global population affected by schizophrenia and bipolar disorder, better awareness and improved diagnostic practices, heightened use of both atypical and typical antipsychotic medications, and an expanding aging population.

The tardive dyskinesia therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.11 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. Factors contributing to this anticipated growth include the escalating burden of mental health disorders, a surge in R&D initiatives, heightened investments from pharmaceutical firms, an increasing inclination towards personalized treatment approaches, and enhanced healthcare infrastructure. Key trends projected for this period include strategic alliances between pharmaceutical companies and research institutions, development of long-acting formulations, introduction of generic options, regulatory benefits like orphan drug status, and innovations in drug delivery technologies.

The rising prevalence of mental health disorders is expected to drive the growth of the tardive dyskinesia therapeutics market in the coming years. Mental health disorders, which impact a person's thoughts, emotions, behaviors, or daily functioning, are increasing due to growing social isolation. The widespread adoption of digital communication and the demands of fast-paced lifestyles have reduced meaningful face-to-face interactions, leading to heightened feelings of loneliness and emotional strain. Tardive dyskinesia therapeutics play a crucial role in supporting individuals with mental health conditions by managing involuntary movement symptoms resulting from long-term antipsychotic use. This, in turn, enhances treatment adherence and overall quality of life. For example, in 2024, the National Alliance on Mental Illness reported that among U.S. individuals aged 18-44, psychosis spectrum and mood disorders are responsible for nearly 600,000 hospitalizations annually. As a result, the increasing occurrence of mental health disorders is a significant factor propelling the tardive dyskinesia therapeutics market.

Leading companies in the tardive dyskinesia therapeutics market are concentrating on the development of advanced products such as once-daily treatment options to ensure more consistent drug levels in the body. These once-daily treatments simplify medication schedules and enhance patient compliance. In May 2024, Teva Pharmaceutical Industries Limited, an Israel-based biopharmaceutical company, received U.S. FDA approval for AUSTEDO XR tablets, designed for adults with tardive dyskinesia and chorea associated with Huntington's disease. AUSTEDO XR provides effective symptom control through a single daily dose and is now offered in four strengths: 30 mg, 36 mg, 42 mg, and 48 mg. The formulation's efficacy has been validated through pivotal clinical trials, emphasizing its role in improving convenience and adherence in patient care.

In February 2024, Teva Pharmaceutical Industries Limited entered a partnership with Jiangsu Nhwa Pharmaceutical Co. Ltd. to promote and distribute AUSTEDO in China. This collaboration leverages Nhwa's established presence in China's neuropsychiatric health sector to broaden access to AUSTEDO. The drug is recognized as the first VMAT2 inhibitor approved by the U.S. FDA for treating tardive dyskinesia and Huntington's disease-related chorea in adults. Jiangsu Nhwa Pharmaceutical Co. Ltd. is a pharmaceutical company based in China.

Major players in the tardive dyskinesia therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Lundbeck A/S, Amneal Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Neurocrine Biosciences Inc., Luye Pharma Ltd., Lannett Co. Inc., SteriMax Inc., Zydus Cadila Healthcare Ltd., Adamas Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, SOM Biotech Ltd., Addex Therapeutics.

North America was the largest region in the tardive dyskinesia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tardive dyskinesia therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tardive dyskinesia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tardive dyskinesia therapeutics market consists of revenues earned by entities by providing services such as drug discovery, clinical trial management, formulation services, and pharmacovigilance. The market value includes the value of related goods sold by the service provider or included within the service offering. The tardive dyskinesia therapeutics market also includes sales of adjunctive medications, patient monitoring devices, drug delivery systems, and screening tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tardive Dyskinesia Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tardive dyskinesia therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for tardive dyskinesia therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tardive dyskinesia therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Tardive Dyskinesia Therapeutics Market Characteristics

3. Tardive Dyskinesia Therapeutics Market Trends And Strategies

4. Tardive Dyskinesia Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Tardive Dyskinesia Therapeutics Growth Analysis And Strategic Analysis Framework

6. Tardive Dyskinesia Therapeutics Market Segmentation

7. Tardive Dyskinesia Therapeutics Market Regional And Country Analysis

8. Asia-Pacific Tardive Dyskinesia Therapeutics Market

9. China Tardive Dyskinesia Therapeutics Market

10. India Tardive Dyskinesia Therapeutics Market

11. Japan Tardive Dyskinesia Therapeutics Market

12. Australia Tardive Dyskinesia Therapeutics Market

13. Indonesia Tardive Dyskinesia Therapeutics Market

14. South Korea Tardive Dyskinesia Therapeutics Market

15. Western Europe Tardive Dyskinesia Therapeutics Market

16. UK Tardive Dyskinesia Therapeutics Market

17. Germany Tardive Dyskinesia Therapeutics Market

18. France Tardive Dyskinesia Therapeutics Market

19. Italy Tardive Dyskinesia Therapeutics Market

20. Spain Tardive Dyskinesia Therapeutics Market

21. Eastern Europe Tardive Dyskinesia Therapeutics Market

22. Russia Tardive Dyskinesia Therapeutics Market

23. North America Tardive Dyskinesia Therapeutics Market

24. USA Tardive Dyskinesia Therapeutics Market

25. Canada Tardive Dyskinesia Therapeutics Market

26. South America Tardive Dyskinesia Therapeutics Market

27. Brazil Tardive Dyskinesia Therapeutics Market

28. Middle East Tardive Dyskinesia Therapeutics Market

29. Africa Tardive Dyskinesia Therapeutics Market

30. Tardive Dyskinesia Therapeutics Market Competitive Landscape And Company Profiles

31. Tardive Dyskinesia Therapeutics Market Other Major And Innovative Companies

32. Global Tardive Dyskinesia Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tardive Dyskinesia Therapeutics Market

34. Recent Developments In The Tardive Dyskinesia Therapeutics Market

35. Tardive Dyskinesia Therapeutics Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기